Rivus Pharmaceuticals has raised $224M across 3 funding rounds.
Rivus Pharmaceuticals launched in July 2021 with a $35 million Series A financing round to develop treatments for cardio-metabolic disease. Chair of Development David Grainger is a co-founder and partner at the venture firm Medicxi, which has backed the company alongside its other biotech bets.
3 funding rounds, the latest highlighted.
Rivus Pharmaceuticals was founded in 2006, United States.
Rivus Pharmaceuticals Launches with $35 Million Series A Financing. $35M raised, led by Longitude Capital, Medicxi.
Rivus Pharmaceuticals Closes $132 Million Series B Financing. $132M raised, led by RA Capital Management.
No filing has been made.
3 dated rounds, newest first.
The routes section explains what is realistically available for a company at this stage.
No. Rivus Pharmaceuticals is a private company; its shares do not trade on a public exchange.
The closest biotechnology/pharmaceuticals peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
